Pfizer and Triana Biomedicines Collaborate on Molecular Glue Discovery for Cancer and Other Diseases in $1.5 Billion Deal

Partnership Details:
Pfizer has entered into a strategic collaboration and licensing agreement with Triana Biomedicines to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

Financial Terms:
Triana Biomedicines will receive an upfront payment of $49 million and is eligible for future milestone payments exceeding $1.5 billion, as well as tiered royalties.

Research Focus:
The collaboration aims to leverage Triana’s target-first and proximity-first molecular glue discovery platform to identify novel molecular glue degraders against multiple targets across various disease areas.

Development Responsibilities:
Triana will lead the discovery and identification of potential development candidates, while Pfizer has the exclusive option for an exclusive license to pursue further preclinical and clinical development.

Strategic Significance:
This collaboration reflects Pfizer’s commitment to exploring cutting-edge technologies to drive potential breakthroughs in oncology and other disease areas.